

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **CHINA NUCLEAR ENERGY TECHNOLOGY CORPORATION LIMITED**

**中國核能科技集團有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 611)**

### **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON FRIDAY, 29 MAY 2026**

Reference is made to the circular dated 30 April 2026 (the “**Circular**”) of China Nuclear Energy Technology Corporation Limited (the “**Company**”). Unless otherwise specified, capitalised terms used herein shall have the same meanings as defined in the above Circular.

The Company announces that at the annual general meeting of the Company held on Friday, 29 May 2026 (the “**AGM**”), all proposed ordinary resolutions (the “**Ordinary Resolutions**”) and the proposed special resolution (the “**Special Resolution**”, together with Ordinary Resolutions, the “**Resolution(s)**”) as set out in the notice of AGM dated 30 April 2026 (the “**AGM Notice**”) were passed on a poll.

As at the date of the AGM, a total of 1,852,036,942 shares of the Company (the “**Shares**”) were in issue and the holders of which (the “**Shareholders**”) were entitled to attend and vote at the AGM in respect of the Resolutions numbered 1 to 7 and 9. The Company has no treasury shares as at the date of AGM.

As stated in the Circular, CD Finance is an associate of Nanshan Holdings. Nanshan Holdings through its ownership in its subsidiary, being Yahgee International (Hong Kong), holding 538,942,750 Shares in total, representing 29.10% of the total issued share capital of the Company as at the date of AGM, is required to abstain from voting on the Resolution numbered 8 in accordance with the Listing Rules. Accordingly, Shareholders holding an aggregate of 1,313,094,192 Shares, representing approximately 70.90% of the total issued share capital of the Company as at the date of the AGM, were entitled to attend and vote at the AGM in respect of Resolution numbered 8.

Save as disclosed above, there were no restrictions on any Shareholders to cast votes on any of the proposed resolutions at the AGM, there was no Share entitling any Shareholders to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of Listing Rules and no Shareholder was required under the Listing Rules to abstain from voting at the AGM. To the best knowledge, information and belief of the Board, there was no party who had stated his/her/its intention in the Circular to vote against the Resolutions at the AGM or to abstain had done so at the AGM.

Except Mr. Wu Rong, Mr. Qiu Wenhe, Mr. Li Xiaofeng and Dr. Su Lixin were unable to attend the AGM due to their other business engagements, all other directors of the Company attended the AGM in person or by electronic means.

The branch share registrar of the Company in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM. The poll results are set out below:

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
1.	To receive, consider and approve the audited consolidated financial statements, the reports of the directors (the “ <b>Directors</b> ”) and the independent auditor of the Company for the year ended 31 December 2025.	1,019,263,378 (100%)	0 (0%)
2.	(a) To re-elect Mr. Wang Haoying as a non-executive Director.	1,019,263,378 (100%)	0 (0%)
	(b) To re-elect Mr. Wu Rong as an executive Director.	1,017,794,768 (99.86%)	1,468,610 (0.14%)
	(c) To re-elect Mr. Qiu Wenhe as an executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)
	(d) To re-elect Mr. Liu Genyu as an executive Director.	1,017,794,768 (99.86%)	1,468,610 (0.14%)
	(e) To re-elect Mr. Li Xiaofeng as an executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
	(f) To re-elect Ms. Du Ruili as an executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)
	(g) To re-elect Dr. Xu Shiqing as an independent non-executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)
	(h) To re-elect Dr. Su Lixin as an independent non-executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)
	(i) To re-elect Mr. Wang Ruzhang as an independent non-executive Director.	1,019,216,768 (99.99%)	46,610 (0.01%)
3.	To authorise the board of directors of the Company (the “ <b>Board</b> ”) to fix the Directors’ remuneration.	1,019,216,768 (99.99%)	46,610 (0.01%)
4.	To re-appoint Ernst & Young as auditor of the Company until the conclusion of the Company’s next annual general meeting and to authorise the Board to fix their remuneration.	1,019,216,768 (99.99%)	46,610 (0.01%)
5.	To give a general mandate to the Directors to issue, allot and deal with, or transfer out of treasury additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution.	1,017,794,768 (99.86%)	1,468,610 (0.14%)
6.	To give a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares) as at the date of passing of this resolution.	1,019,216,768 (99.99%)	46,610 (0.01%)

<b>ORDINARY RESOLUTIONS</b>		<b>Number of Votes (%)</b>	
		<b>For</b>	<b>Against</b>
7.	To extend the general mandate granted to the Directors to issue, allot and deal with, or transfer out of treasury additional shares of the Company by the aggregate number of the shares repurchased by the Company.	1,017,794,768 (99.86%)	1,468,610 (0.14%)
8.	<p>(i) To confirm, approve and ratify the Financial Services Framework Agreement and the transactions contemplated thereunder; and</p> <p>(ii) any one Director be and is authorised to do all such acts and things, to sign and execute such documents or agreements or deeds on behalf of the Company, including under seal of the Company, where applicable, and to do such other things and to take all such actions as he/she considers necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Financial Services Framework Agreement and all transactions contemplated thereunder, and to agree to such variation, amendments or waiver or matters relating thereto as he/she sees fit.</p>	478,852,018 (99.69%)	1,468,610 (0.31%)

SPECIAL RESOLUTION		Number of Votes (%)	
		For	Against
9.	<p>(i) To adopt the proposed amendments to the existing Bye-laws of the Company.</p> <p>(ii) To adopt the new Bye-laws of the Company in substitution for and to the exclusion of the existing Bye-laws of the Company.</p> <p>(iii) To authorise any one Director or company secretary or registered office provider of the Company to do all such acts and things and execute all such documents and make all such arrangement as they shall, in their absolute discretion, deem necessary or expedient to give effect to the proposed amendments to the existing bye-laws of the Company and the proposed adoption of the new bye-laws of the Company.</p>	<p>1,019,216,768 (99.99%)</p>	<p>46,610 (0.01%)</p>

As more than 50% of the votes were cast in favour of each of the Ordinary Resolutions and more than 75% of the votes were cast in favour of the Special Resolution, all Resolutions were duly passed as ordinary resolutions and special resolution of the Company. For details of the Resolutions, Shareholders may refer to the AGM Notice and the Circular.

By Order of the Board  
**China Nuclear Energy Technology Corporation Limited**  
**Wang Haoying**  
*Chairman*

Hong Kong, 29 May 2026

*As at the date of this announcement, the non-executive Director of the Company is Mr. Wang Haoying (Chairman); the executive Directors of the Company are Mr. Wu Rong (Vice Chairman), Mr. Qiu Wenhe (Vice Chairman), Mr. Liu Genyu, Mr. Li Xiaofeng and Ms. Du Ruili; and the independent non-executive Directors of the Company are Dr. Xu Shiqing, Dr. Su Lixin and Mr. Wang Ruzhang.*